Image Credit: depositphotos.com
A recent study from UCLA has unveiled promising insights into enhancing cancer immunotherapy by focusing on dendritic cells, a type of immune cell crucial for activating T cells. While immunotherapy has shown transformative effects for some cancer patients, 60 to 80 percent do not respond effectively. This new research suggests that creatine, a well-known supplement among athletes, could be an essential fuel source for dendritic cells, potentially improving patient outcomes.
Dendritic cells are vital in the immune response, capturing tumor fragments and presenting them to T cells, which are the frontline defenders against cancer. However, many existing cancer immunotherapies bypass this initial step, often resulting in suboptimal responses in patients. Researchers at UCLA observed that the gene responsible for the creatine transporter was significantly more active in tumor-infiltrating dendritic cells compared to healthy cells, indicating a possible link between creatine and immune function.
To further investigate, the team conducted experiments to assess the effects of creatine on dendritic cells. They found that removing the creatine transporter led to reduced survival and activation of these cells, impairing their ability to stimulate T cells. Conversely, administering daily creatine injections in mouse models of melanoma significantly slowed tumor growth and enhanced dendritic cell activity within tumors.
Metabolic analyses revealed that creatine boosts ATP levels in dendritic cells, which is crucial for their energy demands, especially in the competitive environment of tumor cells. This increase in energy helps maintain the inflammatory signaling pathways necessary for the activation of these immune cells.
In human cell studies, creatine was shown to enhance the activation of monocyte-derived dendritic cells, which are often utilized in cancer vaccines. The researchers propose that incorporating creatine into the manufacturing process of these vaccines could improve their effectiveness before administration.
While these findings are promising, they are based on preclinical models and human cells, and further clinical trials are necessary to determine the effects of creatine supplementation in cancer patients. Creatine monohydrate has a long history of safe use as a dietary supplement, which may facilitate clinical testing. The UCLA team is working towards prospective trials to explore whether creatine can improve outcomes for patients undergoing immunotherapy.
This research underscores the importance of supporting the entire immune response, not just focusing on T cells, in the fight against cancer. If these results translate into clinical practice, creatine could become a low-cost yet effective component of immunotherapy protocols.
Check out the original article here: Source link
